Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: A randomized, controlled, dose-response trial

Vaccine

Volumn 18, Issue 16, 2000, Pages 1700-1706

  Trannoy, Emanuelle ^a   Berger, Rosemarie ^b   Holländer, Georges ^b   Bailleux, Fabrice ^c   Heimendinger, Pierre ^a   Vuillier, Delphine ^c   Creusvaux, Hervé ^c  

^a Pasteur Merieux Connaught (PMC)   (France)

^b Kinderspital   (Switzerland)

^c NONE

Author keywords

Cellular immune response; Elderly immunodeficiency; Interferon gamma; Live attenuated vaccine; Precursor T cell frequency; Varicella zoster virus

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4; LIVE VACCINE; PNEUMOCOCCUS VACCINE; VARICELLA ZOSTER VACCINE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; ELDERLY CARE; HERPES ZOSTER; HUMAN; IMMUNOCOMPETENCE; INFECTION PREVENTION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION;

AGED; AGING; ANTIGENS, VIRAL; B-LYMPHOCYTES; CHILD; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; LYMPHOCYTE ACTIVATION; MIDDLE AGED; PHENOTYPE; T-LYMPHOCYTES; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 0033962640     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00510-1     Document Type: Article

References (20)

1. Arvin A. The T-lymphocyte response to varicella zoster virus and its relevance to vaccine development. Review in Medical Virology. 4:1994;161-175.
2. Gershon A., Silverstein S. Live attenuated varicella vaccine for prevention of herpes zoster. Biologicals. 25:1997;227-230.
3. Ragozzino M.W., Melton L.J., Kurland L.T., Chu C.P., Perry H.O. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore). 61:1982;310-316.
4. Berger R., Florent G., Just M. Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect. Immun. 32:1981;24-27.
5. Jenkins D.E., Redman R.L., Lam EM, Liu C., Lin I., Arvin A.M. Interleukin (IL)-10, IL-12, and interferon-gamma production in primary and memory immune responses to varicella-zoster virus. J. Infect. Dis. 178:1998;940-948.
6. Zhang Y., White C.J., Levin M., Hayward A. Cytokine production in varicella-zoster virus-stimulated lymphocyte cultures. Neurology. 45:1995;S38-S40.
7. Arvin A.M., Sharp M., Smith S., et al. Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. J. Immunol. 146:1991;257-264.
8. Diaz P.S., Smith S., Hunter E., Arvin A.M. T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J. Immunol. 142:1989;636-641.
9. Sadzot-Delvaux C., Arvin A.M., Rentier B. Varicella-zoster virus IE63, a virion component expressed during latency and acute infection, elicits humoral and cellular immunity. J. Infect. Dis. 178:(Suppl. 1):1998;S43-S47.
10. Sharp M., Terada K., Wilson A., et al. Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. J. Infect. Dis. 165:1992;852-858.
11. Berger R, Amstutz I, Just M, Just V, Luescher D. Booster vaccination of healthy adults with VZV antibody but without a VZV-specific cell-mediated immune response. Antiviral Res 1985;1(Suppl.):267-71.
12. Levin M.J., Barber D., Goldblatt E., et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J. Infect. Dis. 178:(Suppl. 1):1998;S109-S112.
13. Hardy I., Gershon A.A., Steinberg S.P., LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group [see comments]. N. Engl. J. Med. 325:1991;1545-1550.
14. Sauerbrei A., Prager J., Hengst U., Zintl F., Wutzler P. Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant. 20:1997;381-383.
15. Berger R., Trannoy E., Hollander G., Bailleux F., Rudin C., Creusvaux H. A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. J. Infect. Dis. 178:(Suppl. 1):1998;S99-103.
16. Hayward A.R., Buda K., Levin M.J. Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults. Viral. Immunol. 7:1994;31-36.
17. Del Prete G. The concept of type-1 and type-2 helper T cells and their cytokines in humans. International Review of Immunology. 16:1998;427-455.
18. Bergen R.E., Diaz P.S., Arvin A.M. The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content. J. Infect. Dis. 162:1990;1049-1054.
19. Arvin A.M., Kinney-Thomas E., Shriver K., et al. Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. J. Immunol. 137:1986;1346-1351.
20. Huang Z., Vafai A., Hayward A.R. Specific lysis of targets expressing VZV gpI or gp IV by CD4+ clones. J. Virol. 66:1999;2664-2669.